Ethyl 4-[(2-phenylimidazo[1,2-a]pyrimidin-3-yl)methyl]piperazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Ethyl 4-[(2-phenylimidazo[1,2-a]pyrimidin-3-yl)methyl]piperazine-1-carboxylate
• 英文别名: ethyl 4-[(2-phenylimidazo[1,2-a]pyrimidin-3-yl)methyl]piperazine-1-carboxylate
• 化学式: C₂₀H₂₃N₅O₂
• 分子量: 365.4
• InChiKey: FOVNPGHECBZWIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS
  申请人：Bayer Aktiengesellschaft

  公开号：US20200109155A1

  公开（公告）日：2020-04-09

  The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

  本发明涉及新型的二氮杂双环取代咪唑[1,2-a]嘧啶衍生物，以及制备它们的方法。本发明还涉及它们的单独或联合使用用于治疗和/或预防疾病，以及用于制备药物用于治疗和/或预防疾病，特别是用于治疗和/或预防呼吸障碍，包括睡眠相关呼吸障碍，例如阻塞性和中枢性睡眠呼吸暂停和鼾症。